Charles Schwab Investment Management Inc. Has $103.28 Million Position in Universal Health Services, Inc. $UHS

Universal Health Services reported a beat on the quarter with EPS of $5.69 versus consensus $4.66 and revenue of $4.50 billion versus $4.32 billion, driving 13.4% YoY revenue growth; net margin was 8.09% and ROE 19.47%. The company announced a $0.20 quarterly dividend (annualized $0.80, 0.3% yield) and consensus FY EPS is estimated at $15.92. Institutional positioning is high (86.05% ownership) with several funds modestly adjusting stakes (e.g., Charles Schwab trimmed to 570,117 shares worth $103.3M), while insiders sold material blocks (Director Elliot Sussman 965 shares at $225.70; Director Warren Nimetz 3,817 shares at $223.30), and analysts remain mixed with a consensus price target near $232.64.

Analysis

Market structure: UHS’s beat (Q vs. consensus: EPS $5.69 vs $4.66; revenue +13.4% y/y) strengthens its pricing power in behavioral health and acute-care referral flow; legacy hospital peers (HCA, Tenet/THC) are the main losers if UHS converts more outpatient/behavioral capacity. Suppliers (staffing agencies) and short-term debt markets benefit from stronger cash generation; insurance payers face marginal cost pressure. Institutional ownership at ~86% compresses float and amplifies moves on flows.

Risk assessment: Key tail risks are regulatory action on behavioral-health licensing/reimbursement or a Medicaid/Medicare rate shock (a severe reimbursement cut of 5–10% could shave ~10–20% off EPS), litigation in behavioral units, and sustained labor inflation; probability medium but impact high. Near-term (days–weeks) expect volatility around earnings residuals and insider selling headlines; medium-term (3–12 months) fundamentals driven by admissions mix and margin recovery; long-term (12–36 months) depends on organic growth plus M&A execution and capital allocation (dividends negligible at 0.3% yield).

Trade implications: Tactical long exposure sized 2–3% of portfolio on pullbacks >5% from current levels, target $260–$270 (Raymond James) in 9–12 months, stop-loss 12%. Defined-risk option play: buy a 6–9 month 230/270 call spread to capture upside while capping loss; pair trade: long UHS vs short HCA (HCA) sized 0.7:1 to exploit relative margin acceleration. Reduce exposure to staffing-heavy healthcare REITs and small-cap behavioral pure-plays that face higher litigation/regulatory gamma.

Contrarian angles: Consensus “Hold” (avg PT $232.64) underweights the EPS beat and 19.5% ROE — market may be overly focused on insider sales (16% insider ownership still high). If UHS sustains margins for two quarters, upside re-rating to $260–$280 is credible; conversely, a regulatory headline would be an asymmetric buying opportunity—establish size on any >12% drop within 60 days.

Key Decisions for Investors

• Establish a 2–3% long position in UHS (NYSE:UHS) on a pullback to ≤ $220 or incrementally over the next 4–8 weeks; target $260–$270 within 9–12 months, stop-loss at 12% below cost.
• Implement a defined-risk options trade: buy a 6–9 month UHS 230/270 call spread sized to equal 1–2% portfolio risk (max loss = premium) to capture upside to analyst targets while limiting downside.
• Execute a relative-value pair: long UHS vs short HCA (ratio 0.7:1) for a 6–12 month horizon to exploit UHS’s behavioral health momentum and higher ROE; trim if relative spread narrows by >20% or UHS misses next quarter.
• Reduce exposure by 50% to small-cap behavioral/psychiatric peers and staffing-heavy healthcare names (next 3–6 months) to hedge regulatory/labor-cost risk; redeploy proceeds into UHS long or cash.
• Monitor three near-term catalysts over next 30–90 days: (1) CMS/State reimbursement guidance for behavioral health, (2) UHS same-facility volume trends in next two quarters, (3) any litigation/regulatory filings—if two triggers turn negative, cut UHS exposure to <1%.